Alembic Pharma Receives USFDA Approval for Lung Cancer Drug Binimetinib
Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Binimetinib tablets, used to treat lung cancer and melanoma with a BRAF V600E mutation. The drug is therapeutically equivalent to Mektovi Tablets by Array BioPharma Inc. Alembic is eligible for 180 days of generic exclusivity and now holds a total of 248 USFDA ANDA approvals. The market for Binimetinib tablets is estimated at $282 million through September 2026.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (55/100). Lens Score 43/100.
Outlets measured: news18, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–55/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 15 Nov, 10:28 am. Other outlets followed.
- 1
